Nektar Therapeutics Shares Drop After Mid-Stage Hair Loss Drug Data Release
Shares of Nektar Therapeutics (NKTR) fell close to an eight-month low following the release of mid-stage trial data for its hair loss drug candidate, rezpegaldesleukin. The REZOLVE-AA trial evaluated a twice-monthly subcutaneous injection as a late-line treatment option. The mixed results from the clinical study failed to meet all endpoints or show strong enough efficacy to excite investors, leading to downward pressure on Nektar's stock price. This development comes amid ongoing challenges for biotech firms in advancing novel therapies into commercial markets without robust data backing their effectiveness. Investors are now assessing whether further trials can improve the drug’s profile and justify continued investment.
Tickers: $NKTR
Topics: biotech clinical trials hair loss treatment stock price movement